{"id":"placebo-apremilast","safety":{"commonSideEffects":[{"rate":"15–20","effect":"Diarrhea"},{"rate":"10–15","effect":"Nausea"},{"rate":"8–12","effect":"Headache"},{"rate":"5–10","effect":"Upper respiratory tract infection"},{"rate":"5–8","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE-4, apremilast prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP levels in immune cells. This suppresses the production of pro-inflammatory cytokines such as TNF-α, IL-2, and IL-17, while promoting anti-inflammatory mediators, thereby reducing systemic inflammation.","oneSentence":"Apremilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:38.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Behçet's disease-associated oral ulcers"}]},"trialDetails":[{"nctId":"NCT03036995","phase":"PHASE2","title":"Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-03-20","conditions":"Vitiligo","enrollment":80},{"nctId":"NCT07325266","phase":"PHASE2","title":"Human Laboratory Study of Apremilast for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2026-04-01","conditions":"Alcohol Use Disorder, Alcohol Misuse","enrollment":100},{"nctId":"NCT04227314","phase":"PHASE3","title":"Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2022-04-10","conditions":"Recurrent Aphtous Stomatitis","enrollment":134},{"nctId":"NCT04804553","phase":"PHASE3","title":"Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis","status":"RECRUITING","sponsor":"Amgen","startDate":"2022-03-17","conditions":"Active Juvenile Psoriatic Arthritis","enrollment":60},{"nctId":"NCT07029529","phase":"PHASE2","title":"Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Alcohol Use Disorder","enrollment":120},{"nctId":"NCT06122649","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-11-27","conditions":"Plaque Psoriasis","enrollment":203},{"nctId":"NCT06588738","phase":"PHASE3","title":"A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alumis Inc","startDate":"2024-08-20","conditions":"Plaque Psoriasis","enrollment":840},{"nctId":"NCT06586112","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alumis Inc","startDate":"2024-07-25","conditions":"Plaque Psoriasis","enrollment":840},{"nctId":"NCT04528082","phase":"PHASE3","title":"Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease","status":"RECRUITING","sponsor":"Amgen","startDate":"2021-09-09","conditions":"Behçet Disease","enrollment":60},{"nctId":"NCT06108544","phase":"PHASE3","title":"A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-11-06","conditions":"Plaque Psoriasis","enrollment":1108},{"nctId":"NCT06088043","phase":"PHASE3","title":"A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-11-06","conditions":"Plaque Psoriasis","enrollment":693},{"nctId":"NCT03774875","phase":"PHASE4","title":"A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-03-28","conditions":"Psoriasis","enrollment":277},{"nctId":"NCT04908189","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-15","conditions":"Psoriatic Arthritis","enrollment":729},{"nctId":"NCT05174065","phase":"PHASE3","title":"Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-03-08","conditions":"Palmoplantar Pustulosis","enrollment":176},{"nctId":"NCT06863493","phase":"PHASE2, PHASE3","title":"Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients","status":"NOT_YET_RECRUITING","sponsor":"SFA Therapeutics","startDate":"2025-06-01","conditions":"Psoriasis (PsO)","enrollment":125},{"nctId":"NCT03701763","phase":"PHASE3","title":"Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-12-19","conditions":"Psoriasis","enrollment":245},{"nctId":"NCT03747939","phase":"PHASE4","title":"Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-12-31","conditions":"Arthritis, Psoriatic","enrollment":310},{"nctId":"NCT04057937","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-10-16","conditions":"Palmoplantaris Pustulosis","enrollment":90},{"nctId":"NCT03721172","phase":"PHASE3","title":"Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-03-11","conditions":"Psoriasis","enrollment":595},{"nctId":"NCT03777436","phase":"PHASE3","title":"An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-02-11","conditions":"Psoriasis","enrollment":289},{"nctId":"NCT02684123","phase":"NA","title":"Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-02","conditions":"Alopecia Areata","enrollment":30},{"nctId":"NCT02425826","phase":"PHASE4","title":"A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-04-20","conditions":"Parapsoriasis","enrollment":221},{"nctId":"NCT03656666","phase":"PHASE2","title":"The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2019-09-24","conditions":"Lichen Planus of Vulva, Female Genital Disease","enrollment":42},{"nctId":"NCT03624127","phase":"PHASE3","title":"Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-08-07","conditions":"Psoriasis","enrollment":666},{"nctId":"NCT03611751","phase":"PHASE3","title":"An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-07-26","conditions":"Psoriasis","enrollment":1020},{"nctId":"NCT03175549","phase":"PHASE2","title":"Medication Development in Alcoholism: Apremilast Versus Placebo","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2017-11-01","conditions":"Alcohol Use Disorder","enrollment":51},{"nctId":"NCT04590586","phase":"PHASE3","title":"Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-11-24","conditions":"COVID-19","enrollment":515},{"nctId":"NCT03168256","phase":"PHASE3","title":"CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Can-Fite BioPharma","startDate":"2018-09-15","conditions":"Plaque Psoriasis","enrollment":528},{"nctId":"NCT01307423","phase":"PHASE3","title":"Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-12-09","conditions":"Psoriatic Arthritis","enrollment":529},{"nctId":"NCT01690299","phase":"PHASE3","title":"Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-10-01","conditions":"Psoriasis, Psoriatic Arthritis","enrollment":250},{"nctId":"NCT01232283","phase":"PHASE3","title":"Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-11-22","conditions":"Plaque Psoriasis","enrollment":413},{"nctId":"NCT01194219","phase":"PHASE3","title":"Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09-09","conditions":"Plaque Psoriasis","enrollment":844},{"nctId":"NCT03160248","phase":"PHASE2","title":"An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2017-07-05","conditions":"Nummular Eczema, Eczema, Dermatitis Eczema","enrollment":31},{"nctId":"NCT02307513","phase":"PHASE3","title":"A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-12-30","conditions":"Behçet's Syndrome","enrollment":207},{"nctId":"NCT02802735","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-06-22","conditions":"Pharmacokinetics","enrollment":28},{"nctId":"NCT03836885","phase":"PHASE2","title":"Apremilast - Oral Lichen Planus Trial","status":"WITHDRAWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-11-21","conditions":"Oral Lichen Planus","enrollment":""},{"nctId":"NCT00456092","phase":"PHASE2","title":"Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-03-05","conditions":"Psoriatic Arthritis","enrollment":204},{"nctId":"NCT00866359","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-08-01","conditions":"Behcet Syndrome","enrollment":111},{"nctId":"NCT01172938","phase":"PHASE3","title":"Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-06-02","conditions":"Psoriatic Arthritis","enrollment":504},{"nctId":"NCT03123471","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-05-16","conditions":"Psoriasis","enrollment":303},{"nctId":"NCT01583374","phase":"PHASE3","title":"Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-02","conditions":"Ankylosing Spondyloarthritis","enrollment":490},{"nctId":"NCT01925768","phase":"PHASE3","title":"Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-09-04","conditions":"Psoriatic Arthritis","enrollment":219},{"nctId":"NCT01285310","phase":"PHASE2","title":"Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2010-12-09","conditions":"Rheumatoid Arthritis","enrollment":237},{"nctId":"NCT02087943","phase":"PHASE2","title":"Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-06","conditions":"Dermatitis, Atopic Dermatitis","enrollment":191},{"nctId":"NCT02289417","phase":"PHASE2","title":"Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-01-08","conditions":"Ulcerative Colitis","enrollment":170},{"nctId":"NCT01988103","phase":"PHASE2","title":"Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-09","conditions":"Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica","enrollment":254},{"nctId":"NCT00773734","phase":"PHASE2","title":"Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-09-01","conditions":"Psoriasis, Plaque-type Psoriasis","enrollment":352},{"nctId":"NCT01212770","phase":"PHASE3","title":"PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09-30","conditions":"Psoriatic Arthritis","enrollment":505},{"nctId":"NCT01212757","phase":"PHASE3","title":"PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09-27","conditions":"Psoriatic Arthritis","enrollment":488},{"nctId":"NCT00606450","phase":"PHASE2","title":"Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04-01","conditions":"Psoriasis","enrollment":260},{"nctId":"NCT00944658","phase":"PHASE2","title":"Spondylitis Trial of Apremilast for Better Rheumatic Therapy","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2009-08","conditions":"Ankylosing Spondylitis","enrollment":38},{"nctId":"NCT02412644","phase":"PHASE4","title":"Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2015-05-28","conditions":"Plaque Psoriasis","enrollment":29},{"nctId":"NCT02400749","phase":"PHASE4","title":"Apremilast in Palmo-Plantar Psoriasis","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2015-05","conditions":"Palmo-plantar Psoriasis","enrollment":100},{"nctId":"NCT03049267","phase":"PHASE2","title":"Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis","status":"COMPLETED","sponsor":"M.B.A. van Doorn","startDate":"2017-02-02","conditions":"Hidradenitis Suppurativa","enrollment":20},{"nctId":"NCT03553433","phase":"PHASE4","title":"Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2018-06","conditions":"Psoriasis of Scalp, Psoriasis Vulgaris","enrollment":90},{"nctId":"NCT02963779","phase":"PHASE1","title":"A Study of LY2775240 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-12","conditions":"Healthy","enrollment":35},{"nctId":"NCT01204138","phase":"PHASE2","title":"Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2010-09","conditions":"Arthritis, Rheumatoid","enrollment":""},{"nctId":"NCT01250548","phase":"PHASE2","title":"The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2010-05","conditions":"Rheumatoid Arthritis","enrollment":34},{"nctId":"NCT01200472","phase":"PHASE2","title":"Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-08","conditions":"Erosive Osteoarthritis of the Hand","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Otezla","CC-10004"],"phase":"marketed","status":"active","brandName":"Placebo-Apremilast","genericName":"Placebo-Apremilast","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apremilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}